Cochlear Limited provides implantable hearing solutions principally in the Americas, Europe, the Middle East, Africa and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories and Baha bone conduction implants. Cochlear Limited is based in Sydney, Australia.
| Revenue (Most Recent Fiscal Year) | $1.59B |
| Net Income (Most Recent Fiscal Year) | $99.97M |
| PE Ratio (Current Year Earnings Estimate) | 23.54 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 20.44 |
| Pre-Tax Margin (Trailing 12 Months) | 9.11% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 2.15 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.32 |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $1.67 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 130.80M |
| Free Float | -- |
| Market Capitalization | $5.94B |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 0.71 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.79 |
| Dividend Yield (Based on Last Quarter) | 1.74% |